spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

6th Annual Cancer Vaccines Conference

SMI - 6th annual Cancer Vaccines Conference

27-28 September 2017
Copthorne Tara Hotel, London UK

Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.

SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.

Aimed at an audience of senior scientists and oncology specialists involved in targeted vaccines and drug research, Cancer Vaccines 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of cancer immunotherapy. The 6th annual show will capture expert insight by honing in on new pathways with novel vaccines and immunotherapies, drug formulations, personalised treatment, immune check-point inhibitors, plus more.

Join us this September for strategic direction on vaccine commercialisation and arm yourself with the key requirements and tools for successful vaccine development through informed guidance delivered by a top panel of speakers.

Featured Speakers:

Steve Doberstein, Senior Vice President and Chief Scientific Officer, Nektar
Kandeepan Ganeshalingam, Executive Director, Therapeutic Area Head Oncology, MSD
Fatema Legrand, Senior Clinical Scientist, Genentech
David Giljohann, CEO, Exicure
Steve Doberstein, Senior Vice President and Chief Scientific Officer, Nektar
Agnete Fredriksen, Chief Scientific Officer, Vaccibody
Mads Hald Andersen, Professor and Vice-Director, Centre for Cancer Immune Therapy, Copenhagen University Hospital; Founder, IO Biotech
Rose-Ann Padua, Research Director, INSERM
Zahra Jawad, Group Leader in Discovery Technology, Agenus

Exclusive highlights in 2017:

Exploring personalising cancer vaccines, characterising and applying the outside in approach in cancer vaccine development
Maximising the therapeutic potential of cancer vaccines in combination with immune checkpoint inhibitors
In depth case study examples of peptide, DNA, neoantigen and MHC based vaccine development
Assessing the use of preclinical data for cancer vaccines

Cancer Vaccines 2017 is sponsored by Northwest Biotherapeutics
phone +44 (0) 207 827 6012
email kwilliams@smi-online.co.uk
web bit.ly/2rAmHA3
email Copthorne Tara Hotel, London
 
Print this page
Send to a friend
   
spacer
Industry Events

4th Annual Formulation & Drug Delivery Congress

8-9 May 2018, London, UK

Oxford Global are proud to present our hugely popular 4th Annual Formulation & Drug Delivery Congress, 8th 9th May 2018, London, UK.Over 300 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will gather for over 40 presentations and case studies focused on the key issues in large molecule and small molecule drug formulation and drug delivery.
More info >>

Banner of Clinical_Trial_New_England_events_95 on Samedan

Banner of ChinaBio_Events_102 on Samedan
White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>


News and Press Releases

York Health Economics Consortium offers an updated training event

Health economics evidence is a key element in much health services research and particularly in health technology assessments, including submissions for NICE single technology appraisals. Identifying economic evidence to inform submissions involves searches in a range of databases and uses a variety of strategies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement